Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk  by Little, M.A. et al.
Severity of primary MPGN, rather than MPGN type,
determines renal survival and post-transplantation
recurrence risk
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1Department of Nephrology and Transplantation, Beaumont Hospital, Dublin, Ireland
Previous studies suggested that membranoproliferative
glomerulonephritis (MPGN) type II has a worse renal survival
and an unacceptable risk of recurrence post transplantation.
We hypothesised that other factors may determine this risk.
We analysed all cases (n¼ 70) of MPGN diagnosed by renal
biopsy in Ireland from 1972 to 1995. We used Cox regression
analysis to determine factors that were independently
predictive of renal failure. MPGN II had more crescent
formation and mesangial proliferation (Po0.05). Mean
follow-up duration was 13.8 years, during which time 41
(58.6%) developed end-stage renal failure (ESRF). The median
time to ESRF was 8.3 years (95% confidence interval 5.7–10.9)
and 5-, 10-, and 20-year probabilities of ESRF were 32, 54, and
70%, respectively. Multivariate analysis revealed that severity
of interstitial fibrosis (Po0.05), crescent formation (Po0. 01)
and mesangial proliferation (Po0.05) were independently
associated with ESRF. Decade of diagnosis, age, MPGN type,
and creatinine or complement level at baseline did not
predict renal survival in this model. In 21 (49%) of the 43
renal transplants, MPGN recurred. Younger age at initial
diagnosis (Po0.01) and the presence of crescents on the
original biopsy (Po0.005) were independently associated
with recurrence on multivariate analysis. MPGN type was not
associated with recurrence in this model. Contrary to
previous reports, after controlling for crescent formation,
MPGN II was not associated with more ESRF or recurrence in
the allograft. It is therefore the more aggressive glomerular
changes associated with MPGN II, rather than the disease
type per se, that determine outcome.
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Membranoproliferative glomerulonephritis (MPGN) is an
uncommon cause of chronic glomerulonephritis in the
developed world.1–3 It typically affects children and young
adults with a mean age at onset ranging from 8 to 30 years.4
MPGN is a disease that lacks any unique serological markers
and has no pathognomonic clinical features, but rather is a
histologically defined entity characterised by global and
diffuse mesangial cell proliferation with migration of
mesangium into the glomerular capillary walls, producing
an apparent split or double-contoured appearance. It is seen
in association with a variety of infections and other systemic
diseases. In particular, it has become apparent that, in many
parts of the world, hepatitis C virus (HCV), with or without
associated cryoglobulinaemia, is an important aetiological
factor for MPGN type I.5,6 Several longitudinal outcome
studies have been performed, most of which were published
in the early 1990s. Of note, most of these studies were
performed before the aetiological importance of HCV was
appreciated. Therefore, we do not have accurate knowledge of
the natural history in the idiopathic (non-HCV associated)
form of this disease.
MPGN is classified into three subtypes on the basis of
pathological features identified by light, immunofluorescence
and electron microscopy. Type I MPGN is characterised by
subendothelial deposits in the capillary wall. In type II
MPGN, elongated electron dense densities are seen within
the glomerular, tubular and Bowman’s capsular basement
membrane; hence, it is also referred to as ‘linear dense
deposit disease’. Previous studies have indicated a recurrence
rate of 90% following renal transplantation for this type of
MPGN.7 Type III MPGN is a variant of type I in which there
are many subepithelial as well as subendothelial deposits.8,9
Of note, we have previously reported that familial MPGN
III may occur and is linked to a locus on chromosome 1,8,9 an
area that encompasses the regulators of complement cluster,
suggesting a role for disordered complement regulation in the
pathogenesis of this disease.
Because of the rarity of MPGN, guidance for physicians is
based on case series performed mainly before 1990. The
majority of these were published before the importance of
HCV was known. In addition, factors potentially predictive
of end-stage renal failure (ESRF) or recurrence of primary
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disease in a transplant were frequently considered in isolation
from each other. We were interested in what factors were
independently predictive of outcome (ESRF and recurrence
in the renal allograft) when analysed by multivariate analysis.
Therefore, we performed a retrospective cohort analysis on a
large group of patients with primary MPGN.
RESULTS
Histopathological characteristics at presentation
Of the 70 patients with primary idiopathic MPGN, 30
patients had type I disease (43%), 23 had type II (33%), and
17 had type III (24%). The percentages of cellular crescents,
glomerular sclerosis, interstitial fibrosis and degree of
mesangial proliferation are summarised in Figure 1. The
light microscopic changes were very similar for types I and
III. There was a significant increase in the percentage of fresh
crescents (Po0.05) and degree of mesangial proliferation
(Po0.05) in type II MPGN.
Clinical characteristics at presentation
The clinical characteristics at presentation are summarised in
Table 1. Mean age was 24.9 years (range 3–76) and 41 (59%)
were male. Type II patients were younger (P¼ 0.001) and
exhibited a female preponderance (Po0.05), which contrasts
with a slight male preponderance among those with type I or
III disease. All type III patients had nephrotic-range
proteinuria at presentation compared to two-thirds of those
with type I or II disease (Po0.05). There was no significant
difference in the prevalence of hypocomplementaemia at
presentation.
Renal survival
Univariate analysis. During the period of follow-up, 41
patients (58.6%) became dialysis dependent. Univariate
analyses of factors associated with this outcome measure
are summarised in Table 2. There were 11 deaths (16%)
during the period of follow-up, all of which occurred after
the development of ESRF. Figure 2 depicts the unadjusted
probability of developing ESRF over time. The overall
median time to ESRF from diagnosis was 8.3 years (95%
confidence interval (CI) 4.4–12.3) and 5-, 10-, and 20-year
probabilities of ESRF were 32, 54, and 70%, respectively.
Using life table survival analysis, the presence of nephrotic-
range proteinuria (Po0.01), cellular crescents on biopsy at
diagnosis (Po0.005), degree of mesangial proliferation
(Po0.005) and degree of interstitial fibrosis (Po0.01) were
associated with a higher propensity to ESRF (Figure 3).
Interestingly, neither MPGN type (P¼ 0.6; Figure 3), treat-
ment modality (P¼ 0.5) nor complement profile at pre-
sentation (P¼ 0.9) was associated with ESRF. There was no
cohort effect, with the same probability of ESRF observed in
the three cohorts (P¼ 0.3). Renal survival probability was the
same in patients with accurate treatment data (n¼ 59) and
those without (n¼ 11, P¼ 0.5).
We evaluated a predictive scoring system for two groups of
patients. Firstly, in those patients with no cellular crescents,
o20% interstitial fibrosis and pþ 2 mesangial proliferation
(n¼ 16), median renal survival was 13.8 years and 10-year
probability of ESRF was 12%. This compared to a median
renal survival of 6.4 years and 10-year ESRF probability of
69% in those without this triad (n¼ 54; hazard ratio 0.21,
95% CI 0.15–0.70, Po0.005). Secondly, nephrotic patients
with at least one cellular crescent (n¼ 18) exhibited a
median renal survival of 4.5 years and 10-year ESRF
probability of 92%. This compared to a median renal
survival of 11.9 years and 10-year ESRF probability of 41%
in those without the combination of nephrotic syndrome and
crescentic nephritis (n¼ 52; hazard ratio 3.0, 95% CI
2.0–11.9, Po0.0005).
Multivariate analysis. Using multivariate Cox regression
analysis, the degree of interstitial fibrosis (Po0.05), degree of
mesangial proliferation (Po0.05) and the presence of at least
one cellular crescent at diagnosis (Po0.01) were indepen-
dently associated with ESRF (Table 3).
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Figure 1 | Histopathological characteristics at diagnosis. (a) Mean
cellular crescent fraction was 3.171.2, 15.374.3 and 5.373.5% for
types I, II and III, respectively. (b) Respective values for percentage
of glomeruli sclerosed were 9.772.4, 5.972.9 and 15.475.9%, for
percentage of interstitium fibrosed (c) 21.972.3, 18.972.1 and
25.775.0% and for degree of mesangial proliferation (d) 2.370.1,
2.770.2 and 2.070.2. The bars represent the mean7s.e.m. *Po0.05.
Table 1 | Clinical characteristics of the patients at
presentation according to MPGN type
Type I Type II Type III P-value
Age (years) (mean,
range)
33.2 (5–76) 13.7 (4–34) 26 (3–66) 0.001
Male (n, %) 22 (73) 8 (34) 11 (64) 0.02
Creatinine (mg/dl)
(median, IQR)
0.9 (0.6–1.9) 0.8 (0.6–1.3) 0.8 (0.7–1.4) 0.23
Nephrotic at
presentation (n, %)a
18 (64) 15 (65) 15 (100) 0.03
Low C3 at
presentation (n, %)b
12 (46) 5 (29) 7 (58) 0.28
IQR=interquartile range.
an=66.
bn=55.
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Recurrence in the renal allograft
Univariate analysis. There were 43 renal transplants in
33 patients. In 21 (49%) of these, MPGN recurred after a
median of 4.7 years. In all of these, the diagnosis was
confirmed immuno-histologically and with electron micro-
scopy. Of those who suffered a recurrence of MPGN in the
graft, 14 (67%) ultimately lost their graft. The median time to
graft failure was 7.5 years. Given that the data are censored
for graft loss owing to patient death, this is likely to represent
a reduction in graft half-life (a view supported by a recent
report suggesting increased rates of graft loss in patients with
recurrent MPGN type II).10
Considering the probability of recurrence over time using
life table analysis, younger age at initial diagnosis (Po0.05),
the degree of mesangial proliferation (Po0.05) and crescent
formation on the original biopsy (Po0.05) were associated
Table 2 | Univariate analysis of factors potentially associated
with the development of ESRF
ESRF No ESRF P-value
Age (years) (mean, s.d.) 24.1 (18.5) 26.1 (19.7) 0.4
Gender (n, %)
Male 25 (61) 16 (39) 0.83
Female 16 (55) 13 (45)
MPGN classification (n, %)
I 16 (53) 14 (47) 0.59
II 15 (65) 8 (35)
III 10 (59) 7 (41)
Nephrotic at presentation (n, %) 32 (67) 5 (28) 0.009
Low C3 (n, %)
Yes 18 (58) 13 (42) 0.91
No 13 (54) 11 (46)
Cohort (n, %)
1970s 14 (70) 6 (30) 0.27
1980s 16 (53) 14 (47)
1990s 11 (55) 9 (45)
Creatinine (mg/dl) (median, IQR) 0.9 (0.6–2.0) 0.9 (0.6–1.2) 0.06
Treatment modality (n, %)
None 4 (44) 5 (56) 0.5
Steroid 5 (27) 15 (73)
BPa 19 (64) 11 (36)
Mesangial proliferation (mean, s.d.) 2.6 (0.9) 2.0 (0.6) 0.002
Interstitial fibrosis (%) (mean, s.d.) 25.2 (11.5) 17.7 (14.2) 0.008
Cellular crescents (%) (mean, s.d.) 12.1 (18.2) 1.7 (4.0) 0.003b
ESRF, end-stage renal failure; MPGN, membranoproliferative glomerulonephritis;
IQR, interquartile range; BP, bloal pressure
The variables are compared with Kaplan–Meier life table analysis using the log-rank
test.
aBP: antihypertensive therapy alone.
bComparing those with crescents with those without crescents; IQR: interquartile
range.
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Figure 2 | Unadjusted Kaplan–Meier survival curve depicting
likelihood of reaching ESRF. Overall median time to ESRF from
diagnosis was 8.3 years (95% CI 4.4–12.3) and 5-, 10- and 20-year
probabilities of ESRF were 32, 54 and 70%, respectively. Error bars
depict the s.e.m.
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Figure 3 | Kaplan–Meier survival curves depicting the likelihood
of reaching ESRF based on the following. (a) The presence or
absence of nephrotic syndrome at diagnosis. The 5-year probability
of ESRF was 37% in the presence of nephrotic syndrome (’) and
12% in its absence (m, **Po0.01). (b) The presence or absence of at
least one cellular crescent at diagnosis. The 5-year probability of ESRF
was 52.5% with one or more crescents (’) and 22.5% with no
crescents (m, ***Po0.005). (c) The tertiles of interstitial fibrosis. The
5-year probability of ESRF was 58% with 425% (.), 21% with
10–25% (m) and 8% with o10% interstitial fibrosis (’, ***Po0.001).
(d) MPGN type. There was no significant difference between the
three groups, with 5-year ESRF probability of 34, 34 and 35% for
types I, II and III, respectively. Error bars depict the s.e.m.
Table 3 | Multivariate Cox regression analysis of factors
potentially associated with ESRF
Variable P-value Hazard ratio (95% CI)
Age 0.62 1.02 (0.7–2.9)a
Gender 0.55 0.76 (0.4–1.7)b
MPGN type 0.89 1.21 (0.6–1.9)c
Creatinine at presentation 0.20 1.54 (0.7–2.8)d
Nephrotic syndrome 0.12 1.96 (0.8–6.2)e
Crescent on initial biopsy 0.002 10.2 (4.4–18.7)f
Degree of mesangial proliferation 0.03 1.72 (1.3–6.4)g
Degree of interstitial fibrosis 0.04 14.52 (1.2–27.8)h
aMPGN, membranoproliferative glomerulonephritis; CI, confidence interval
o21 versus 421 years.
bMale versus female.
cType II versus type I/III.
d40.9 versus o0.9 mg/dl.
eYes versus no.
fYes versus no.
g42 versus o2.
h420 versus o20%.
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with recurrence and there was a trend towards an increased
risk of recurrence in type II MPGN (P¼ 0.1) (Figure 4,
Table 4).
Multivariate analysis. As many of the factors described
above are inter-related, we performed multivariate Cox
regression analysis (Figure 5, Table 5). When variables
indicative of glomerulonephritis severity (crescent formation,
mesangial proliferation) were built into this model, the trend
towards recurrence seen with MPGN type II was no longer
present. Using this model, younger age at initial diagnosis
(Po0.05) and the presence of crescents on the original
biopsy (Po0.005) were independently associated with
recurrence on multivariate analysis. All of the increase in
recurrence seen in type II was statistically accounted for by
the fact that these patients had more severe glomerulo-
nephritis, as manifested by mesangial proliferation and
crescent formation. The increase in recurrence risk in
younger patients was not accounted for by the fact that
there was a shorter interval between ESRF occurrence and
transplantation. In fact, younger patients had to wait slightly
longer for their transplant (median time from ESRF to
transplant: 15 versus 18 months in those 416 and o16
years, respectively).
DISCUSSION
In this large cohort of patients with primary idiopathic
MPGN with prolonged follow-up, we have applied detailed
statistical analysis in an attempt to identify those factors that
are predictive of progressive renal failure and recurrence of
the disease in the renal allograft. Our data suggest that it is
the severity of acute glomerular injury on the initial biopsy
(most notably the degree of mesangial proliferation and the
presence of cellular crescents) that predicts risk of ESRF, not
MPGN type per se. Those with MPGN type II appeared to do
worse overall and this was because they had more severe
glomerulonephritis.
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Figure 4 | Kaplan–Meier survival curves comparing the likelihood
of recurrence in a renal transplant according to the following.
(a) MPGN type. There was a trend towards a higher probability of
recurrence in MPGN II with 5-year probability of recurrence 36, 76 and
34% for types I (’), II (m) and III (.), respectively (P¼ 0.1). (b) The
presence of cellular crescents on the initial biopsy. The probability of
recurrence was higher in those with crescents (’, 5-year recurrence
probability 72%) than in those without (m, 5-year recurrence
probability 35%, Po0.05). (c) Age tertile. Younger patients had a
higher probability of recurrence: 69, 56 and 15% 5-year recurrence
probability in those o9 (’), 9–19 (m) and 419 years (.),
respectively (Po0.05). (d) The degree of mesangial proliferation on
the initial biopsy. The probability of recurrence was higher in those
with a mesangial proliferation score of 3–4 (m) compared to those
with a score o2 (m, *Po0.05). Error bars depict the s.e.m.
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Figure 5 | Cox regression multivariate analysis of variables
predicting recurrence of MPGN post transplantation, plotted at
the mean of the covariates. (a) The covariates included were age,
gender, MPGN type and the presence of nephrotic syndrome at first
diagnosis. (b) To these were added histological variables (crescent
fraction, degree of mesangial proliferation and interstitial fibrosis on
the initial biopsy). (a) When histological variables are excluded from
the analysis, there appears to be a trend towards increased
recurrence risk with type II MPGN. (b) However, when the histological
variables are taken into account, that is, controlling for mesangial
proliferation and crescent formation, the association between MPGN
type II and recurrence risk completely disappears (the curves for type
I and III MPGN are superimposed).
Table 4 | Univariate analysis of factors potentially associated
with recurrence of MPGN in the renal allograft
Recurrence No recurrence P-value
MPGN type (n, %)
I 6 (46) 7 (54) 0.1
II 11 (61) 7 (39)
III 4 (33) 8 (67)
Age (years) (mean, range) 14.2 (6–29) 22.9 (5–66) 0.02
Gender (n, %)
Male 15 (50) 15 (50) 0.2
Female 6 (46) 7 (54)
Nephrotic-range proteinuria
at presentation (n, %)
Yes 16 (48) 17 (52) 0.51
No 2 (40) 3 (60)
Complement at presentation (n, %)
Low 7 (47) 8 (53) 0.24
Normal 10 (55) 8 (45)
Crescents at presentation
(%) (mean, s.d.)
19.9 (20.9) 8.2 (15.3) 0.03a
Mesangial proliferation
(mean, s.d.)
3.0 (0.9) 2.4 (0.7) 0.02
MPGN, membranoproliferative glomerulonephritis;
The variables are compared with Kaplan–Meier life table analysis using the log-rank
test.
aComparing those with crescents on initial biopsy with those with no crescents.
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We have also identified a group with excellent (88% after
10 years) long-term renal survival (those with no cellular
crescents, o20% interstitial fibrosis and pþ 2 mesangial
proliferation), and a group with very poor (8% after 10 years)
long-term renal survival (nephrotic patients with at least one
crescent). Among the clinical variables tested, only nephrotic-
range proteinuria at presentation predicted an increased risk
of ESRF on multivariate analysis.
Idiopathic MPGN appears to be an uncommon disease in
Ireland, diagnosed in just 1.8% of all native renal biopsies
and accounting for 3.7% of all primary glomerulonephritis.
Our study is representative of MPGN in the entire Republic
of Ireland as, during the time period under study, most
biopsies performed in the country were analysed at
Beaumont Hospital. The majority of our patients presented
with proteinuria in the nephrotic range associated with
hypocomplementaemia. Overall, renal prognosis was poor,
with half of our patients reaching ESRF in a little over 8 years.
The absence of any cohort effect by decade of diagnosis
suggests that we have made little progress in the treatment of
this disease in the last 30 years.
With regard to risk of recurrent disease following renal
transplantation, this appears to be unrelated to MPGN type.
Indeed, on multivariate analysis, the only factors predictive of
recurrence risk were younger age at initial diagnosis (69%
recurrence risk at 5 years if agedo9 years compared with 0%
if aged 419 years; Po0.05) and the presence of cellular
crescents on the initial biopsy (72% recurrence risk at 5 years
in those with crescents compared to 35% risk in those
without; Po0.05). Of note, we were unable to account for
factors such as possible inherited deficiencies of the
complement cascade, which may have an important impact
on recurrence risk. In instances where a clear family history
of MPGN was present,8,9 the case was not included in our
study. Therefore, our findings do not necessarily apply to this
group of patients.
On review of the literature in this field, our reported
incidence of MPGN is commensurate with that reported
elsewhere in the developed world.1–3 Unusually, although in
many parts of the world MPGN is now considered to be HCV
associated in most cases,5,6,11–14 this does not appear to
pertain in Ireland. We have detected just one case of HCV-
associated MPGN since introduction of routine testing for
hepatitis C in Ireland in 1991. Furthermore, no case of
hepatitis C has yet come to light among the patients with
MPGN described in this report, and retrospective testing of
available stored sera has not yielded any cases of previously
undiagnosed hepatitis C. It may be that HCV-associated
MPGN, while common in the USA and Japan, may not be as
prevalent in Europe, and Ireland is certainly not unique in
respect of this lack of association.15–17
The impact of MPGN type on renal survival is a point of
particular interest given the widely held perception that type
II disease is generally associated with a worse prognosis18,19
and carries a significantly higher risk of recurrence following
renal transplantation.7,20–23 In fact, the evidence base for this
assertion is relatively poor. Any apparent association between
type II MPGN and poorer renal survival is likely to be
illusory, merely reflecting the fact that type II disease is more
likely to be associated with more aggressive initial histological
changes (see Figure 1). This illustrates the pitfalls of analysing
predictive variables in isolation from each other. One
previous study (published in Russian)24 has adopted a
multivariate approach, although no attempt was made to
analyse the interaction between MPGN subtype and
histological variables, as in our case. Our findings challenge
the dogma that there is something different about MPGN
type II that renders it a more aggressive disease with a
particular propensity to recur in the renal allograft.
The strengths of our study are its comparatively large
sample size, long duration of follow-up and the multivariate
approach to analysing factors (both clinical and histological)
that may predict outcome. The inclusion of both adult and
paediatric subjects and the exclusion of cases of MPGN
secondary to HCV infection also strengthen the study. The
main limitations are its retrospective nature and the limited
availability of data regarding treatment (a potential con-
founding variable).
In conclusion, it is the severity of initial glomerular injury,
rather than the MPGN type, that determines renal survival.
When advising individual patients on what the future holds,
we should look first to the initial renal histology for guidance
rather than considering the MPGN type. In the context of
transplantation, a diagnosis of type II MPGN should not of
itself be considered a contraindication (even in the live-
related setting), but rather one should review the details of
the initial histology and take cognisance of the age at first
diagnosis. The corollary also holds true, in that we should
exercise caution in those patients with type I or III disease
who presented at a younger age with a crescentic glomerulo-
nephritis.
SUBJECTS AND METHODS
Study population
We performed our study at Beaumont Hospital, Dublin, the
largest tertiary referral centre for nephrology in the Republic
Table 5 | Multivariate Cox regression analysis of factors
potentially associated with recurrence in the renal allograft
Variable P-value Hazard ratio (95% CI)
Age 0.04 3.71 (1.02–7.7)a
Gender 0.13 1.99 (0.7–5.0)b
MPGN type 0.78 1.61 (0.5–4.8)c
Nephrotic at presentation 0.42 1.52 (0.4–5.1)d
Crescent on initial biopsy 0.005 6.88 (2.5–12.9)e
Degree of mesangial proliferation 0.65 0.95 (0.6–1.4)f
aMPGN, membranoproliferative glomerulonephritis; CI, Confidence interval
o21 versus 421.
bMale versus female.
cType II versus type I/III.
dYes versus no.
eYes versus no.
fo2 versus 42.
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of Ireland and the national centre for renal transplantation.
The majority (80–85%) of renal biopsies performed in
Ireland (native and transplant, adult, and paediatric) are
reported by the Renal Pathology service at Beaumont.25 It is
therefore well placed to provide a representative picture of
the pattern of MPGN disease in Ireland as a whole. We
analysed each of the subtypes separately to determine
differences in their clinical features, prognosis and rate of
recurrence following renal transplantation.
Beaumont Hospital provides a diagnostic renal histo-
pathology service to a population of approximately three
million people. Using the laboratory database of Beaumont’s
renal pathology service, we attempted to identify all
instances of MPGN demonstrated on native renal biopsy
spanning the 23-year period from 1972 to 1995. Clinical data
were drawn from patient medical records and from the
tissue-typing database. The date on which the initial renal
biopsy was performed was assigned as the date of diagnosis.
All cases were followed until death or 1/4/2004 to
ensure long-term follow-up. During this time, 2886 native
renal biopsies were analysed, of which 1372 (47.4%)
showed evidence of glomerulonephritis. Of those with
glomerulonephritis, 240 (17.5%) demonstrated an immune
deposition disease with a membranoproliferative pattern
of injury.
We excluded from our analysis all patients with MPGN
secondary to other identifiable conditions. Diagnoses in this
group included systemic lupus erythematosus, hepatitis B/C,
cryoglobulinaemia, and chronic infection (for example,
infective endocarditis or infected ventriculo-atrial shunt).
Specifically, after 1991, all sera were tested for HCV
antibodies and only one instance of HCV-associated MPGN
was identified (and excluded). Other causes of glomerular
injury with a potential membranoproliferative pattern, such
as chronic thrombotic microangiopathy and fibrillary
glomerulonephritis, were also excluded.
A total of 83 patients remained (6.1%), who were
designated as having idiopathic MPGN; of these, 13 were
lost to follow-up (three type I, five type II, and five type III),
leaving 70 cases, which form the basis of this report. The
mean age at time of biopsy was 24.9 years (range 3–76) and
41 (59%) were male. In order to exclude a cohort effect, we
defined three cohorts: before 1979 (n¼ 20), 1979–1989
(n¼ 30) and after 1989 (n¼ 20). Treatment modalities were
subdivided into the following groups: (1) no treatment
(n¼ 9), (2) steroid treatment (with or without additional
antihypertensive therapy n¼ 20) and (3) antihypertensive
therapy alone (n¼ 30). Accurate data on treatment were not
available in 11 patients. Patients were assessed until the time
of last follow-up or death. The patients were followed for a
total of 968 patient-years (mean follow-up 13.8 years, range
1.2–30.3).
Histopathology
We subdivided the cases by histological classification into
types I–III according to the biopsy report with blinded review
of histology, immunofluorescence and electron microscopy
performed in all cases. We quantified the percentage of
cellular glomerular crescents (defined as occupying 410% of
the glomerulus), sclerosed glomeruli, and amount of
interstitium fibrosed on the renal biopsy. In addition,
we scored the degree of mesangial proliferation from 0 to
4. Clinical follow-up data were collected on serum creatinine
at presentation (n¼ 68), presence or absence of nephrotic-
range proteinuria (43 g/24 h, n¼ 67) and complement
C3 level at presentation (‘normal’ or ‘low’, n¼ 55). The
need for long-term renal replacement therapy and the
clinical course following renal transplantation, including
recurrence of primary disease, were recorded. All cases of
recurrence of MPGN were diagnosed by histological
immunofluorescent and ultrastructural examination of a
transplant renal biopsy.
Literature review
To place our study in the proper context, we conducted a
comprehensive literature review using Medline (1966–2005)
and Embase (1983–2005). The following search terms were
used: MPGN; hypocomplementaemic glomerulonephritis;
lobular glomerulonephritis; membrane proliferative glomerulo-
nephritis; membranoproliferative nephritis; membranous
proliferative glomerulonephritis; mesangiocapillary glomerulo-
nephritis; mesangioproliferative glomerulonephritis; rapidly
progressive glomerulonephritis. A total of 4415 Medline and
Embase entries were reviewed. We examined 81 studies
(excluding case reports) reporting outcome in idiopathic
MPGN, the majority of which were retrospective and
uncontrolled. Details of a selection of frequently cited key
studies are listed in Table 6 to allow comparison with our
own data.
Statistical analysis
Skewed data sets were expressed as the median and
interquartile range and analysed using non-parametric tests.
Normally distributed data sets were expressed as mean and
standard error of the mean. The probability of developing
ESRF over time and recurrence of MPGN in a renal
transplant were analysed with Kaplan–Meier survival plots
using SPSS 9.0 software. Univariate analysis of factors
potentially associated with the development of ESRF or
recurrence in the renal allograft were compared with the log-
rank test, with censoring in the event of patient death or
passing the date 1/4/2004. Continuous variables (for
example, age, creatinine at presentation, degree of interstitial
fibrosis) were divided into tertiles for this purpose. Those
factors associated with ESRF or recurrence on univariate
analysis at a significance level of Po0.2 (in addition to age
and gender) were analysed using a multivariate Cox
regression proportional hazards model. The assumption of
proportionality was tested for each variable. A P-value of
p0.05 was considered to indicate statistical significance and
all tests were two-tailed.
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